FDA to review Hana nausea therapy

The FDA has agreed to review Hana Biosciences' oral spray to prevent nausea. Hana has filed for regulatory approval of Zensana Oral Spray, a therapy that has been tested to prevent nausea among cancer patients treated with chemotherapy and radiotherapy as well as postoperative nausea and vomiting. Hana filed for FDA approval in June.

"We plan to continue working closely with the FDA during the review," said Mark Ahn, Hana president and chief executive, in a statement. "Subject to FDA approval, we look forward to a potential commercial launch in the United States in the first half of 2007."

- see the AP report on Hana

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.